This suggests that analysts have very recently bumped up their estimates for ZGNX, giving the stock a Zacks Earnings ESP of 2.63% heading into earnings season. Why is this Important? A positive reading for the Zacks Earnings ESP …
Today's Most Active Call & Put Options of the S&P 500 » FactSet Research Systems Inc. (FDS) options are showing a volume of 2,132 contracts thus far today. That number of contracts represents approximately 213,200 underlying …
With that in mind, let's take a closer look at Zogenix's business and see what CAPS investors are saying about the stock right now. Sources: S&P Capital IQ and Motley Fool CAPS. On CAPS, 38% of the 47 members who have rated …
AOL4y
Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that at the annual general meeting of shareholders held …
Stock Advisor returns as of August 1, 2017 This video was recorded on July 26, 2017. Kristine Harjes: Let's move on to our final company of the day. This one is called Zogenix, their ticker is ZGNX, and they have a market cap of $320 million. …
Zogenix Inc's (ZGNX.O) stock fell 20 percent, making it the top percentage loser on the Nasdaq on Friday, after the specialty pharmaceutical company forecast full-year revenue below analysts' estimates. Zogenix's outlook reflected …
The phase 3 studies being conducted by Zogenix are much larger, and late-stage studies still have a high failure rate, so the upcoming data in September is critical to this stock's ability to continue climbing. Assuming the readout from the …
NWI1mon
Register for your complimentary reports at the links given below. Zogenix Inc.'s stock lost 1.43%, to close the day at …